Juvenile Rheumatoid Arthritis - Pipeline Insight, 2024

This “Juvenile Rheumatoid Arthritis - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Juvenile Rheumatoid Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Juvenile Rheumatoid Arthritis Understanding

Juvenile Rheumatoid Arthritis: Overview

Juvenile rheumatoid arthritis (JRA) is the most common chronic rheumatologic disease in children and is one of the most common chronic diseases of childhood. The etiology is unknown, and the genetic component is complex, making clear distinctions between the various subtypes difficult. A new nomenclature, juvenile idiopathic arthritis (JIA), is being increasingly used to provide better definition of subgroups. Symptoms may appear during episodes (flare-ups). Or they may be ongoing (chronic). Each child’s symptoms can vary. Symptoms may include: Swollen, stiff, and painful joints in the knees, hands, feet, ankles, shoulders, elbows, or other joints, often in the morning or after a nap, Eye inflammation, Warmth and redness in a joint, Less ability to use one or more joints, Fatigue, Decreased appetite, poor weight gain, and slow growth, High fever and rash (in systemic JIA), Swollen lymph nodes. Diagnosing JIA may be difficult. There is no single test to confirm the disease. Various treatments can effectively manage and minimize the effects of JIA. Healthcare providers usually recommend a combination of treatments to relieve pain and swelling and to maintain movement and strength.

Juvenile Rheumatoid Arthritis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Juvenile Rheumatoid Arthritis pipeline landscape is provided which includes the disease overview and Juvenile Rheumatoid Arthritis treatment guidelines. The assessment part of the report embraces, in depth Juvenile Rheumatoid Arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Juvenile Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Juvenile Rheumatoid Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Juvenile Rheumatoid Arthritis.

Juvenile Rheumatoid Arthritis Emerging Drugs Chapters

This segment of the Juvenile Rheumatoid Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Juvenile Rheumatoid Arthritis Emerging Drugs

Baricitinib: Eli Lilly and Company Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib disrupts the activation of downstream signalling molecules and proinflammatory mediators. The drug is currently in Phase III stage of development for the treatment of patients with Juvenile RheumatoidArthritis.

AIN457: Novartis AIN457 (Secukinumab) interferes in the psoriasis pathologic process by selectively binding to IL-17A and thereby preventing IL-17A interaction with the IL-17 receptor expressed on, for example, keratinocytes. The drug is in Phase III clinical trial for the treatment of children with Juvenile RheumatoidArthritis.

Juvenile Rheumatoid Arthritis: Therapeutic Assessment

This segment of the report provides insights about the different Juvenile Rheumatoid Arthritis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Juvenile Rheumatoid Arthritis

There are approx. 10+ key companies which are developing the therapies for Juvenile Rheumatoid Arthritis. The companies which have their Juvenile Rheumatoid Arthritis drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Juvenile Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Juvenile Rheumatoid Arthritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Juvenile Rheumatoid Arthritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Juvenile Rheumatoid Arthritis drugs.

Juvenile Rheumatoid Arthritis Report Insights

• Juvenile Rheumatoid Arthritis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Juvenile Rheumatoid Arthritis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Juvenile Rheumatoid Arthritis drugs?
• How many Juvenile Rheumatoid Arthritis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Juvenile Rheumatoid Arthritis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Juvenile Rheumatoid Arthritis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Juvenile Rheumatoid Arthritis and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.